Company Analysis BioMarin Pharmaceutical
1. Summary
Advantages
- Current debt level 16.02% is below 100% and has decreased over 5 years from 18.08%.
Disadvantages
- Price (67.38 $) is higher than fair price (15.53 $)
- Dividends (0%) are below the sector average (0.541%).
- The stock's return over the last year (-32.07%) is lower than the sector average (-12.5%).
- The company's current efficiency (ROE=3.39%) is lower than the sector average (ROE=9.61%)
Similar companies
2. Share price and performance
2.1. Share price
2.2. News
2.3. Market efficiency
| BioMarin Pharmaceutical | Healthcare | Index | |
|---|---|---|---|
| 7 days | 0.3% | 2.5% | 0.2% |
| 90 days | -11.5% | -17.8% | 1.5% |
| 1 year | -32.1% | -12.5% | 22.9% |
BMRN vs Sector: BioMarin Pharmaceutical has significantly underperformed the "Healthcare" sector by -19.57% over the past year.
BMRN vs Market: BioMarin Pharmaceutical has significantly underperformed the market by -54.95% over the past year.
Stable price: BMRN is not significantly more volatile than the rest of the market on "NASDAQ" over the last 3 months, with typical variations of +/- 5% per week.
Long period: BMRN with weekly volatility of -0.6167% over the past year.
3. Summary of the report
4. Fundamental Analysis
4.1. Stock price and price forecast
Above fair price: The current price (67.38 $) is higher than the fair price (15.53 $).
Price is higher than fair: The current price (67.38 $) is 77% higher than the fair price.
4.2. P/E
P/E vs Sector: The company's P/E (109.95) is higher than that of the sector as a whole (48.77).
P/E vs Market: The company's P/E (109.95) is higher than that of the market as a whole (49.04).
4.2.1 P/E Similar companies
4.3. P/BV
P/BV vs Sector: The company's P/BV (3.72) is lower than that of the sector as a whole (4.83).
P/BV vs Market: The company's P/BV (3.72) is higher than that of the market as a whole (3.17).
4.3.1 P/BV Similar companies
4.4. P/S
P/S vs Sector: The company's P/S indicator (7.62) is lower than that of the sector as a whole (33.77).
P/S vs Market: The company's P/S indicator (7.62) is lower than that of the market as a whole (10.24).
4.4.1 P/S Similar companies
4.5. EV/Ebitda
EV/Ebitda vs Sector: The company's EV/Ebitda (71.81) is higher than that of the sector as a whole (-22.17).
EV/Ebitda vs Market: The company's EV/Ebitda (71.81) is higher than that of the market as a whole (28.32).
5. Profitability
5.1. Profitability and revenue
5.2. Earnings per share - EPS
5.3. Past profitability Net Income
Yield Trend: Negative and has fallen by -16.1% over the last 5 years.
Accelerating profitability: The return for the last year (0%) exceeds the average return for 5 years (-16.1%).
Profitability vs Sector: The return for the last year (0%) is lower than the return for the sector (4135.44%).
5.4. ROE
ROE vs Sector: The company's ROE (3.39%) is lower than that of the sector as a whole (9.61%).
ROE vs Market: The company's ROE (3.39%) is lower than that of the market as a whole (10.71%).
5.5. ROA
ROA vs Sector: The company's ROA (2.45%) is higher than that of the sector as a whole (0.3443%).
ROA vs Market: The company's ROA (2.45%) is lower than that of the market as a whole (6.47%).
5.6. ROIC
ROIC vs Sector: The company's ROIC (0.79%) is lower than that of the sector as a whole (7.63%).
ROIC vs Market: The company's ROIC (0.79%) is lower than that of the market as a whole (10.79%).
7. Dividends
7.1. Dividend yield vs Market
Low yield: The dividend yield of the company 0% is below the average for the sector '0.541%.
7.2. Stability and increase in payments
Unstable dividends: The company's dividend yield 0% has not been consistently paid over the past 7 years, DSI=0.
Weak dividend growth: The company's dividend yield 0% has been growing weakly or stagnant over the past 5 years. Growth over only 0 years.
7.3. Payout percentage
Dividend Coverage: Current payments from income (0%) are at an uncomfortable level.
8. Insider trades
8.1. Insider trading
Insider Buying Exceeds insider sales by 100% over the last 3 months.
8.2. Latest transactions
| Transaction date | Insider | Type | Price | Volume | Quantity |
|---|---|---|---|---|---|
| 12.11.2024 | Guyer Charles Greg Officer |
Purchase | 66.37 | 350 301 | 5 278 |
| 10.05.2024 | BIENAIME JEAN JACQUES Director |
Sale | 81.14 | 1 622 800 | 20 000 |
| 10.05.2024 | BIENAIME JEAN JACQUES Director |
Purchase | 63.1 | 1 262 000 | 20 000 |
| 09.05.2024 | BIENAIME JEAN JACQUES Director |
Sale | 81.62 | 1 632 400 | 20 000 |
| 09.05.2024 | BIENAIME JEAN JACQUES Director |
Purchase | 63.1 | 1 262 000 | 20 000 |
Pay for your subscription
More functionality and data for company and portfolio analysis is available by subscription
